Short answer
RHYTHM PHARMACEUTICALS, INC. (RYTM) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $92M (up 79.6% year over year) with net income of −$41M.
Q3 2026 key financials · XBRL
- Revenue
- $92M
- +79.6% YoY · +29.3% QoQ
- Net income
- −$41M
- +21.8% YoY · +16.1% QoQ
- Operating margin
- -42.6%
- EPS (diluted)
- −$0.61
- +25.6% YoY · +17.6% QoQ
Source: XBRL data from the RHYTHM PHARMACEUTICALS, INC. (RYTM) Q3 2026 10-Q on SEC EDGAR. USD.
RHYTHM PHARMACEUTICALS, INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $92.1M, up 80% YoY from $51.3M, driven by higher domestic and international IMCIVREE volume
- Net loss $41.4M vs $52.9M; operating loss $39.3M vs $52.7M
- U.S. IMCIVREE revenue $67.5M, 73% of product revenue; ex-U.S. revenue $24.7M
- Cash, equivalents and short-term investments $320.9M; operating cash use $56.4M for nine months vs $90.3M
- Outlook: bivamelagon Phase 3 initiation by year-end 2026; $350.0M LGC obligation and term-loan access up to $750.0M increasing fixed obligations
Risk Factors
- Newly added financing risk: November 2, 2026 A&R RIFA and up to $750.0 million term loan introduced additional repayment and covenant obligations
- Most materially updated financial risk: RIFA amendment and term loan could restrict financing, acquisitions, asset sales and other operations
- Regulatory risk: EU IVDR class C companion diagnostics transition deadline reached May 26, 2026
- Operational risk: reliance on specialty pharmacy for significant U.S. revenue makes distributor transitions capable of reducing revenue and cash flows
- Financial risk: $320.9 million cash and investments, with uninsured deposits exposed to financial-institution failure
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other RHYTHM PHARMACEUTICALS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.